Protocols - Page 2 of 6 - PeptideDosing.ca

08 Sep

CJC 1295 NO DAC (10 mg Vial) — Evidence profile

The long-acting CJC-1295 studies commonly cited online cannot automatically support a product labeled NO DAC. This profile distinguishes the labelled product, study findings and evidence limits.

08 Sep

Single Peptides

BPC-157 (10 mg Vial) — Evidence profile

BPC-157 research includes experimental models and registered human studies. Published findings, trial registrations and untested uses should be distinguished. This profile distinguishes the labelled product, study findings and evidence limits.

08 Sep

Single Peptides

Ara-290 (10 mg Vial) — Evidence profile

Cibinetide has been studied in sarcoidosis-associated small-fiber loss. The results need a clear distinction between nerve imaging and symptom relief. This profile distinguishes the labelled product, study findings and evidence limits.

08 Sep

Single Peptides

AOD-9604 (10 mg Vial) — Evidence profile

AOD-9604 is a growth-hormone-fragment analogue. The primary evidence assessed in this profile is from an experimental metabolic study. This profile distinguishes the labelled product, study findings and evidence limits.

08 Sep

Single Peptides

5-Amino-1MQ (50 mg Vial) — Evidence profile

5-Amino-1MQ is a small-molecule NNMT inhibitor studied in experimental metabolic models. This profile distinguishes the labelled product, study findings and evidence limits.

13 May

Peptide Stacks

PT-141 (10 mg) + Melanotan II (10 mg) Stack Dosage Protocol

PT-141 (10 mg) + Melanotan II (10 mg) Stack: dosage protocol — reconstitution 3.0 mL → 3.33 mg/mL with syringe units per dose, supplies, storage and references.

26 Feb

Single Peptides

Testagen (20 mg Vial) — Evidence profile

The short-peptide studies reviewed here use altered animal models. They do not establish a human testosterone or fertility treatment. This profile distinguishes the labelled product, study findings and evidence limits.

26 Feb

Single Peptides

Tesamorelin (10 mg Vial) — Evidence profile

Tesamorelin clinical research includes a defined HIV-associated abdominal-fat setting. The studied outcome is not equivalent to general weight loss. This profile distinguishes the labelled product, study findings and evidence limits.

26 Feb

Single Peptides

TB-500 (10 mg Vial) — Evidence profile

A seven-residue fragment and the full thymosin beta-4 protein have different evidence bases. Establishing which material is present is the first step in interpreting a study. This profile distinguishes the labelled product, study findings and evidence limits.

25 Feb

Single Peptides

SNAP-8 (10 mg, topical) — Evidence profile

The most relevant human evidence reviewed here concerns skin formulations. It does not establish an injectable SNAP-8 treatment. This profile distinguishes the labelled product, study findings and evidence limits.